SG10202012182YA - Compositions and methods for treating rheumatoid arthritis - Google Patents

Compositions and methods for treating rheumatoid arthritis

Info

Publication number
SG10202012182YA
SG10202012182YA SG10202012182YA SG10202012182YA SG10202012182YA SG 10202012182Y A SG10202012182Y A SG 10202012182YA SG 10202012182Y A SG10202012182Y A SG 10202012182YA SG 10202012182Y A SG10202012182Y A SG 10202012182YA SG 10202012182Y A SG10202012182Y A SG 10202012182YA
Authority
SG
Singapore
Prior art keywords
compositions
methods
rheumatoid arthritis
treating rheumatoid
treating
Prior art date
Application number
SG10202012182YA
Other languages
English (en)
Inventor
Deborah Bauer
Alexander Boddy
Neil Graham
Yong Lin
Janie Parrino
Rahul Patel
Adelsberg Janet Van
Hoogstraten Hubert Van
Original Assignee
Sanofi Biotechnology
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by Sanofi Biotechnology, Regeneron Pharma filed Critical Sanofi Biotechnology
Publication of SG10202012182YA publication Critical patent/SG10202012182YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10202012182YA 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis SG10202012182YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16170664 2016-05-20
EP16306111 2016-09-05

Publications (1)

Publication Number Publication Date
SG10202012182YA true SG10202012182YA (en) 2021-01-28

Family

ID=58387910

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202012182YA SG10202012182YA (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis
SG11201807614SA SG11201807614SA (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201807614SA SG11201807614SA (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Country Status (18)

Country Link
US (1) US20190100585A1 (enExample)
EP (1) EP3426295A1 (enExample)
JP (2) JP7166925B2 (enExample)
KR (2) KR20230093522A (enExample)
CN (1) CN109069642A (enExample)
AU (2) AU2017229364A1 (enExample)
BR (1) BR112018067851A2 (enExample)
CA (1) CA3016880A1 (enExample)
CL (1) CL2018002559A1 (enExample)
CR (1) CR20180465A (enExample)
EA (1) EA201892005A1 (enExample)
IL (2) IL308539A (enExample)
MX (2) MX2018010815A (enExample)
PH (1) PH12018501894A1 (enExample)
SG (2) SG10202012182YA (enExample)
TN (1) TN2018000312A1 (enExample)
TW (3) TW202419103A (enExample)
WO (1) WO2017155990A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112020010761A2 (pt) * 2017-11-30 2020-11-24 Bio-Thera Solutions, Ltd. formulação líquida de anticorpo humanizado para o tratamento de doenças relacionadas à il-6
MX2021002422A (es) * 2018-08-29 2021-07-15 Regeneron Pharma Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
TW202521583A (zh) * 2019-01-31 2025-06-01 法商賽諾菲生物技術公司 用於治療幼年原發性關節炎之組成物及方法
TW202106712A (zh) * 2019-04-24 2021-02-16 美商再生元醫藥公司 類風溼性關節炎之診斷及治療方法
MA56116A (fr) 2019-06-04 2022-04-13 Stefano Fiore Compositions et procédés de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoïde
CN117858722A (zh) * 2021-08-18 2024-04-09 百奥泰生物制药股份有限公司 用于治疗il-6相关疾病的包含高浓度人源化抗体的液体制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2385745C (en) * 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
MX2008014804A (es) 2006-06-02 2009-01-27 Regeneron Pharma Anticuerpos de afinidad elevada a receptor de il-6 humano.
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
CN106413748A (zh) * 2013-11-22 2017-02-15 赛诺菲生物技术公司 用于类风湿性关节炎治疗的组合物及使用该组合物的方法

Also Published As

Publication number Publication date
JP2023011711A (ja) 2023-01-24
KR20230093522A (ko) 2023-06-27
JP7166925B2 (ja) 2022-11-08
TW201808993A (zh) 2018-03-16
IL261515B2 (en) 2024-04-01
TW202419103A (zh) 2024-05-16
IL261515B1 (en) 2023-12-01
PH12018501894A1 (en) 2019-05-15
MX2023014841A (es) 2024-01-15
SG11201807614SA (en) 2018-10-30
TW202239767A (zh) 2022-10-16
IL261515A (en) 2018-10-31
BR112018067851A2 (pt) 2019-02-05
EP3426295A1 (en) 2019-01-16
WO2017155990A1 (en) 2017-09-14
US20190100585A1 (en) 2019-04-04
CL2018002559A1 (es) 2019-03-01
AU2017229364A1 (en) 2018-10-25
NZ746988A (en) 2023-10-27
JP7745529B2 (ja) 2025-09-29
JP2019507775A (ja) 2019-03-22
TWI819435B (zh) 2023-10-21
TWI747885B (zh) 2021-12-01
EA201892005A1 (ru) 2019-02-28
CA3016880A1 (en) 2017-09-14
TN2018000312A1 (en) 2020-01-16
AU2024203011A1 (en) 2024-07-11
CR20180465A (es) 2019-03-04
MX2018010815A (es) 2019-01-10
CN109069642A (zh) 2018-12-21
KR20180114955A (ko) 2018-10-19
IL308539A (en) 2024-01-01

Similar Documents

Publication Publication Date Title
IL308841B2 (en) Equipment and methods for handling objects
IL278004A (en) Methods and preparations for treating conditions related to aging
PT3490582T (pt) Composições para utilização no tratamento da mielofibrose
IL251721A0 (en) Preparations and methods for the treatment of diseases of the central nervous system
GB201718801D0 (en) Compositions and methods for inhibiting factor D
SMT202000414T1 (it) Composizioni e metodi per trattare disturbi del snc
PL3224269T3 (pl) Kompozycje i sposoby leczenia zaburzeń OUN
SMT202100113T1 (it) Composizioni e metodi per trattare disturbi del snc
GB2535937B (en) Arginase I for treating rheumatoid arthritis
IL261515A (en) Preparations and methods for the treatment of rheumatoid arthritis
ZA201805490B (en) Methods and compositions for treating hyperhidrosis
PL3071230T3 (pl) Kompozycje do leczenia reumatoidalnego zapalenia stawów oraz sposoby ich stosowania
IL264167A (en) Preparations and methods for the treatment of frontotemporal dementia
IL280824A (en) Methods and compositions for the treatment of rheumatoid arthritis patients
SG11201803485UA (en) Method for producing silazane-siloxane copolymers and the use of such copolymers
IL291266A (en) Preparations and methods for treating infections
PT3220908T (pt) Composições e métodos para o tratamento da endometriose
ZA201703771B (en) Compositions and methods for treating hyperkalemia
ZA201605109B (en) Compositions and methods for treating neutropenia
IL266361A (en) Methods and preparations for the treatment of cartilage damage and arthritis
EP3255994A4 (en) Methods and materials for assessing and treating arthritis
PT3071230T (pt) Composições para o tratamento da artrite reumatoide e métodos de utilização das mesmas
ZA201903005B (en) Methods and compositions for treating atopic dermatitis
HK1260497A1 (en) Compositions and methods for treating rheumatoid arthritis
HK40009682A (en) Methods and compositions for treating myelofibrosis